Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
Results from the Phase III CheckMate 77T study were published today in the New England Journal...
Jennifer Wargo, M.D., elected to the National Academy of Medicine
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine and core member of the James P. Allison...
MD Anderson launches collaborative initiative to reduce breast cancer disparities in Houston area
The University of Texas MD Anderson Cancer Center today announced the launch of Texas Health Equity Alliance for Breast Cancer (THEAL), a...